Established in 2014, Yinnuo Pharmaceutical is a science-driven biopharmaceutical company dedicated to providing innovative, accessible and affordable high-quality pharmaceuticals for patients with metabolic diseases. The company currently has a number of R&D pipelines for indications related to diabetes, obesity, and metabolic dysfunction, and all pipelines are independently developed, have global patents, and have a global R&D and marketing layout. The company's first pipeline product, esupaglutide α (former name: supaglutide, trade name: Innolight), was approved and marketed by China's State Drug Administration in January 2025, making it the first domestically developed humanized long-acting GLP-1 receptor agonist product, which will benefit more diabetics. The company is also developing steatohepatitis indications associated with esupaglutide alpha for weight loss and metabolic dysfunction to meet the huge unmet treatment needs in these diseases. The Yinnuo R&D team is led by national experts and consists of a team of scientists with many years of experience in the development of innovative drugs. Its founder, chairman and CEO, Dr. Wang Qinghua, inventor of isopaglutide α, is a special expert at Fudan University and is responsible for the “Major New Drug Creation” project of the 13th Five-Year National Science and Technology. Professor Wang Qinghua was a tenured professor at the University of Toronto and an executive member of the world-leading Banting Best Diabetes Research Institute. Yinnuo Pharmaceutical has an advanced recombinant protein biopharmaceutical technology platform that can be used for continuous research and development of innovative biopharmaceuticals.